Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

American Journal of Gastroenterology

Volumn 100, Issue 2, 2005, Pages 308-312

  Talwalkar, Jayant A ^a   Angulo, Paul ^a   Keach, Jill C ^a   Petz, Janice L ^a   Jorgensen, Roberta A ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; BACTERIAL CHOLANGITIS; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY COUGH; FATIGUE; FEMALE; HEARTBURN; HUMAN; HUMAN TISSUE; INSOMNIA; INTRAHEPATIC CHOLESTASIS; LIVER FUNCTION TEST; MALE; MASTALGIA; MAXIMUM TOLERATED DOSE; MAYO RISK SCORE; NAUSEA; OPEN STUDY; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SORE THROAT; BLOOD; LIVER; METABOLISM; MIDDLE AGED; SCLEROSING CHOLANGITIS;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CHOLANGITIS, SCLEROSING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS;

EID: 13944277732     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40484.x     Document Type: Article

References (40)

1. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
2. LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
3. Sandborn WJ, Wiesner RH, Tremaine WJ, et al. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993;34:242-6.
4. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9.
5. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992;16:707-14.
6. Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
7. De Maria N, Colantoni A, Rosenbloom E, et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996;43:1472-9.
8. Lindor KD. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
9. van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998;29:417-23.
10. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000;20:97-103.
11. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178-97.
12. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999;40(2 Pt 1):265-8.
13. Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002;40:447-57.
14. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
15. Jones EA, ten Kate FJ, ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1165-9.
16. Jones EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. Hepatology 2002;35:258-62.
17. Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastro 2004;in press.
18. Lankarani KB. Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis. J Clin Gastroenterol 2003;36(1):86.
19. Altschuler EL. Mycophenolate mofetil for primary biliary cirrhosis and sclerosis cholangitis? Nephrol Dial Transplant 1999;14:798-9.
20. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94.
21. Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1:632-40.
22. MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 1983;149(1):39-44.
23. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-51.
24. Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 1992;103:1893-901.
25. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997;25:1049-53.
26. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999;29:1643-8.
27. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:563-75.
28. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002;35:652-7.
29. Lindor KD, Wiesner RH, Colwell LJ, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991;86:57-61.
30. van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Belgian-Dutch PSC Study Group. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Am J Gastroenterol 2000;95:2015-22.
31. Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996;91:511-5.
32. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-7.
33. Duchini A, Younossi ZM, Saven A, et al. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000;31:292-6.
34. Schramm C, Schirmacher P, Helmreich-Becker I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943-6.
35. Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: A pilot study. Dig Dis Sci 1999;44:602-7.
36. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, et al. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: Results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001;13:171-5.
37. Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338-42.
38. Angulo P, MacCarty RL, Sylvestre PB, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002;47:157-61.
39. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
40. Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.